Short Interest in Zhengye Biotechnology Holding Limited (NASDAQ:ZYBT) Grows By 265.5%

Zhengye Biotechnology Holding Limited (NASDAQ:ZYBT) was the recipient of a large growth in short interest in the month of June. As of June 15th, there was short interest totaling 108,354 shares, a growth of 265.5% from the May 31st total of 29,643 shares. Currently, 0.2% of the shares of the company are short sold. Based on an average daily volume of 327,763 shares, the short-interest ratio is presently 0.3 days.

Hedge Funds Weigh In On Zhengye Biotechnology

Several hedge funds and other institutional investors have recently made changes to their positions in the company. Jane Street Group LLC acquired a new stake in shares of Zhengye Biotechnology during the 2nd quarter worth approximately $1,158,000. WINTON GROUP Ltd raised its position in Zhengye Biotechnology by 193.8% during the fourth quarter. WINTON GROUP Ltd now owns 63,297 shares of the company’s stock valued at $73,000 after purchasing an additional 41,750 shares in the last quarter. XTX Topco Ltd lifted its stake in Zhengye Biotechnology by 71.4% during the fourth quarter. XTX Topco Ltd now owns 59,286 shares of the company’s stock worth $68,000 after purchasing an additional 24,697 shares during the last quarter. Invesco Ltd. bought a new stake in Zhengye Biotechnology during the second quarter worth $220,000. Finally, Geode Capital Management LLC acquired a new stake in shares of Zhengye Biotechnology in the 2nd quarter valued at $174,000.

Analysts Set New Price Targets

Separately, Weiss Ratings cut shares of Zhengye Biotechnology from a “sell (d)” rating to a “sell (d-)” rating in a report on Thursday, June 11th. One research analyst has rated the stock with a Sell rating, According to MarketBeat.com, the stock presently has an average rating of “Sell”.

Zhengye Biotechnology Price Performance

NASDAQ:ZYBT opened at $0.71 on Friday. Zhengye Biotechnology has a fifty-two week low of $0.68 and a fifty-two week high of $13.08. The company has a current ratio of 1.14, a quick ratio of 0.82 and a debt-to-equity ratio of 0.03. The stock has a fifty day moving average price of $0.88 and a 200-day moving average price of $1.03.

Zhengye Biotechnology (NASDAQ:ZYBT) last issued its quarterly earnings results on Tuesday, April 28th. The company reported ($0.08) EPS for the quarter. The company had revenue of $3.97 million during the quarter.

Zhengye Biotechnology Company Profile

Zhengye Biotechnology Holding Limited is a veterinary vaccine manufacturer which encompasses research, development, manufacturing and sales of veterinary vaccines, with a focus on livestock vaccine principally in China. Zhengye Biotechnology Holding Limited is based in Jilin, China.